Israel-based startup Nevia Bio (formerly Gina Life), a company developing a machine learning empowered platform for early detection of women's health indications, has announced completion of a $3.1 million Seed Round. The round included MindUP Digital Health Incubator and additional existing investors and was joined by Pitango HealthTech, Alive Israel HealthTech Fund and the Technion investment arms. This seed round comes on the heels of a $1.9 million Pre-Seed Round which brings the company's total funding to date to $5 miilion.

The funding will be used to support the company's clinical trials in ovarian cancer, and to expand its pipeline to additional indications in women's health space, in addition to enhancing the company's data science capabilities.

The Nevia groundbreaking platform decodes information from women's vaginal secretions by applying Machine Learning tools to identify specific proprietary biomarkers signatures to detect the disease in its early and late stages. The use of an untapped biofluid and an innovative scientific approach will enable the detection of women's related diseases, saving and improving women's lives. Specifically, a simple vaginal swab will be collected from women, proprietary protein panel will be measured which will enable detection of ovarian cancer. 

With the support of additional funding and the engagement with healthcare oriented VCs, Nevia is now expanding its clinical collaborations in ovarian cancer and adding additional indications to its pipeline.